Journal
BRAIN
Volume 142, Issue -, Pages 163-175Publisher
OXFORD UNIV PRESS
DOI: 10.1093/brain/awy289
Keywords
APOE4; Alzheimer's disease; exosomes; endosomes; extracellular vesicles
Categories
Funding
- NIH [P01 AG017617, R01 AG057517, R01 AG043375, P01 AG014449, T32-GM066704, T32-AG052909, AG025688]
- Sackler Institute of Graduate Biomedical Sciences, New York University School of Medicine
Ask authors/readers for more resources
APOE4 is a genetic risk factor for ageing-related cognitive decline and Alzheimer's disease. Using human and mouse tissue, Peng etal. report that APOE4 reduces brain exosome production and release. Exosome pathway dysfunction may be the initial event in endosomal-lysosomal-exosomal alterations contributing to neuronal vulnerability and neurodegenerative risk in APOE4-carriers.In addition to being the greatest genetic risk factor for Alzheimer's disease, expression of the ?4 allele of apolipoprotein E can lead to cognitive decline during ageing that is independent of Alzheimer's amyloid- and tau pathology. In human post-mortem tissue and mouse models humanized for apolipoprotein E, we examined the impact of apolipoprotein E4 expression on brain exosomes, vesicles that are produced within and secreted from late-endocytic multivesicular bodies. Compared to humans or mice homozygous for the risk-neutral ?3 allele we show that the ?4 allele, whether homozygous or heterozygous with an ?3 allele, drives lower exosome levels in the brain extracellular space. In mice, we show that the apolipoprotein E4-driven change in brain exosome levels is age-dependent: while not present at age 6 months, it is detectable at 12 months of age. Expression levels of the exosome pathway regulators tumor susceptibility gene 101 (TSG101) and Ras-related protein Rab35 (RAB35) were found to be reduced in the brain at the protein and mRNA levels, arguing that apolipoprotein E4 genotype leads to a downregulation of exosome biosynthesis and release. Compromised exosome production is likely to have adverse effects, including diminishing a cell's ability to eliminate materials from the endosomal-lysosomal system. This reduction in brain exosome levels in 12-month-old apolipoprotein E4 mice occurs earlier than our previously reported brain endosomal pathway changes, arguing that an apolipoprotein E4-driven failure in exosome production plays a primary role in endosomal and lysosomal deficits that occur in apolipoprotein E4 mouse and human brains. Disruption of these interdependent endosomal-exosomal-lysosomal systems in apolipoprotein E4-expressing individuals may contribute to amyloidogenic amyloid- precursor protein processing, compromise trophic signalling and synaptic function, and interfere with a neuron's ability to degrade material, all of which are events that lead to neuronal vulnerability and higher risk of Alzheimer's disease development. Together, these data suggest that exosome pathway dysfunction is a previously unappreciated component of the brain pathologies that occur as a result of apolipoprotein E4 expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available